Brokers Issue Forecasts for Bio-Path Holdings, Inc.’s FY2022 Earnings (NASDAQ:BPTH)

Bio-Path Holdings, Inc. (NASDAQ:BPTHGet Rating) – Equities researchers at HC Wainwright boosted their FY2022 earnings per share (EPS) estimates for shares of Bio-Path in a report issued on Tuesday, November 15th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($1.86) for the year, up from their previous forecast of ($1.87). The consensus estimate for Bio-Path’s current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Bio-Path’s Q4 2022 earnings at ($0.48) EPS, Q1 2023 earnings at ($0.46) EPS, Q2 2023 earnings at ($0.46) EPS, Q3 2023 earnings at ($0.41) EPS, Q4 2023 earnings at ($0.37) EPS and FY2023 earnings at ($1.70) EPS.

Separately, StockNews.com initiated coverage on Bio-Path in a research report on Sunday, November 13th. They issued a “sell” rating on the stock.

Bio-Path Stock Performance

Shares of BPTH opened at $1.48 on Friday. The firm has a market cap of $10.60 million, a P/E ratio of -0.75 and a beta of 1.39. Bio-Path has a 52 week low of $1.29 and a 52 week high of $5.28. The firm’s 50-day simple moving average is $2.97 and its 200 day simple moving average is $3.44.

Hedge Funds Weigh In On Bio-Path

Several institutional investors and hedge funds have recently modified their holdings of BPTH. Mount Yale Investment Advisors LLC acquired a new stake in shares of Bio-Path during the 3rd quarter worth approximately $81,000. Renaissance Technologies LLC bought a new position in shares of Bio-Path in the second quarter worth about $70,000. Virtu Financial LLC acquired a new stake in shares of Bio-Path in the 3rd quarter valued at approximately $39,000. Finally, Citadel Advisors LLC bought a new stake in shares of Bio-Path during the 3rd quarter valued at approximately $35,000. 5.76% of the stock is currently owned by institutional investors and hedge funds.

Bio-Path Company Profile

(Get Rating)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

See Also

Earnings History and Estimates for Bio-Path (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.